Startup Fundraising: What I've Learned

What actually matters when a company decides between non-dilutive funding and a priced round.


Adapted from a set of internal fundraising memos I wrote. Specifics got stripped out. Every number below is illustrative, chosen to show the mechanic rather than to report anyone's books.

Most of what I know about raising money I learned by writing memos nobody outside the company was going to read: what our options were, what each one cost us, and what we had to be able to prove before anyone would take the meeting. This is the part of that work that generalizes.

Think Like Queen Isabella

In the late 1400s, Christopher Columbus set out to secure funding for a seemingly impossible mission: sailing west to reach the East Indies. He was rejected by Portugal, Genoa, and Venice. Most saw the voyage as too risky, too speculative. He was planning on sailing towards the edge of world. But Queen Isabella of Spain thought differently. She invested what today would be roughly $14,000. That decision ultimately yielded Spain an estimated $1.5 trillion in gold and silver.

The lesson isn't to be Columbus. The lesson is to think like Queen Isabella.

Early-stage founders see themselves as visionaries on a quest. When it comes to raising capital you have to flip the script and think like the person writing the cheque. Their job is not to fund dreams — it's to generate returns. Your product doesn't raise capital. Your ability to communicate its value, position it as a transformative opportunity, and make the path to a return obvious is what raises capital.

One Thousand Pitches

A grid of one thousand squares. A cluster of about thirty is shaded grey, and a handful within that cluster are black.
One thousand pitches. Roughly thirty get funded. The black squares are the ones that return the fund.

Out of a thousand pitches an investor may hear, fewer than thirty get funded — and of those, only a handful ever turn a profit. That's a success rate under half a percent.

This is why investors aren't looking for a 2x. They're looking for 100x, because the winners have to pay for everything else in the portfolio. If you walk in offering a solid, sensible double, you have misunderstood the arithmetic of the person you're talking to.

Finding the Right Investors

Three things separate founders who get funded from founders who don't, and none of them is the idea.

Information. Capital markets have changed. Equity crowdfunding, online syndicates, peer-to-peer platforms — there are far more entry points than there were fifteen years ago, and most founders don't know how many of these exist or how to navigate them.

Access. Investors don't fund decks, they fund people, and the single most common route to a funded deal is still a warm referral. A cold pitch, however polished, rarely gets traction.

Expertise. Ideas are cheap; execution is everything. In a 2009 U.S. Bank study, 73% of failed entrepreneurs admitted they overestimated sales, underestimated capital needs, or lacked the operational skill to deliver. Investors know this, which is why proven execution matters more than the pitch.

Even with all three, the odds stay hard. Harvard Business School's Shikhar Ghosh estimates 95% of venture-backed startups fall short of expected returns. Rejection is the default state. The job isn't to eliminate risk — it's to de-risk the opportunity enough that saying yes is easy.

Understanding Dilution

Dilution is the part founders tend to feel emotionally and reason about badly.

Every time you issue new shares, everyone who already holds shares owns a smaller slice of the same company. That's it. The slice shrinks; whether that's good or bad depends entirely on what happens to the size of the pie.

Owning 60% of a company worth $5M is worth less than owning 40% of a company worth $50M. Dilution isn't the enemy — uncompensated dilution is. Giving up 25% of the company to reach a milestone that triples its value is a good trade. Giving up 25% to survive another eight months without changing anything is not.

The practical consequence is that the order you raise in matters as much as the amount. Non-dilutive money first — grants, revenue, strategic partnerships — buys you the milestones that make the dilutive round cost you less equity for the same dollars.

The Capital Readiness Matrix

Different funding paths require different things to already be true about you. This is the most useful thing I built during that work: a grid of what you have against what each path demands, so you can see which doors are actually open.

CriteriaSelf-FundingStrategic PartnerReg CFReg A+VC / PEExit
Board in Place??
C-Suite Leadership??
Key Hires?
Organic Network?
Professional Network?
Proof of Concept
Minimum Viable Product????
Manufacturable Version????
Clinical Validation???
Sales and Business Prep?

✓ in place · ? would help · ✗ needs work · – not required

Filling this in is uncomfortable and that's the point. The version I wrote had one row lit up red across nearly every column: no formal board. A board isn't a governance box to tick — it's credibility, domain expertise, and above all access to the networks where warm referrals come from. It was the cheapest gap to close and the one blocking the most doors.

Sequencing the Raise

Once you know which doors are open, the question becomes what order to walk through them. The paths aren't alternatives — they're a sequence, and each one you complete makes the next cheaper.

(1) Self-FundingStrategic PartnerReg CFReg A+VC / PEPartial Exit
Self-Funding↳ (2)(3a)(3b)(3c)
Strategic Partner↳ (2)(3a)(3b)(3c)
Reg CF↳ (2)(3a)(3b)(3c)
Reg A+
VC / PE
Exit(4)(4)(4)

Phase 1 is internal: self-funded, spent almost entirely on technical infrastructure and the people who build it. You are buying a working thing.

Phase 2 is readiness: recruit the board, run an equity crowdfunding campaign, land a strategic partner. Crowdfunding here is doing double duty — it raises money and it proves market demand, on terms you set rather than terms an early investor sets for you.

Phase 3 is when institutional capital becomes available on decent terms: Reg A+, VC/PE, or an early strategic exit. You arrive with a product, a board, and revenue instead of a deck.

Phase 4 is optionality. Having preserved equity through the early phases, the founders still get to choose.

A Sample Cap Table

Here's the mechanic, with round numbers. A Delaware C-corp authorizing 10,000,000 shares of common stock, founders taking a majority position at incorporation, and a pool carved out for employees before anyone is hired.

ShareholderCommonFully diluted
Founders6,000,00060.0%
Employee option pool1,500,00015.0%
Reserve (board, C-suite, partners)2,500,00025.0%
Total10,000,000100.0%

Founders hold a clear majority. The option pool exists before it is needed, so a hire can be made without renegotiating the whole table.

The 10,000,000-share convention isn't arbitrary. It gives you granularity: a 0.25% grant is 25,000 shares rather than an awkward fraction, and a Reg CF or Reg A+ campaign can price a meaningful minimum investment. Set the par value low at incorporation and the strike price for early employees is effectively zero, which is the whole point of hiring people before you can pay them properly.

The Valuation Simulation

The cap table says who owns what. The valuation simulation says what that ownership is worth as the company moves through the phases above, and what the dilution costs along the way.

CategoryPhase 1 (Y1)Phase 2 (Y2)Phase 2.5 (Y3)Phase 3 (Y3–4)Phase 4 (Exit)
Internal Stake100.0%95.0%90.0%60.0%20.0%
External Stake0.0%5.0%10.0%40.0%80.0%
Valuation$40M$60M$100M$250M
Dilution0.0%−5.0%−10.0%−30.0%−40.0%
Funding / Exit Target$0$2M$3M$30M$100M
Additional Founder Injection$1M$4M$5M$0$0
Cumulative Bankroll$1M$7M$15M$45M$45M+

Two things to read off it. The first is that the internal stake and the valuation have to be read together, never separately: the stake falls from 100% to 20%, but the number it is a percentage of goes from nothing to $250M, and phase 4 puts $100M on the table besides. Dilution is the price of the bankroll. The only question is whether the bankroll bought more than it cost.

The second is that the founder injections stop after phase 2.5. Ten million dollars goes in across the first three phases and nothing after — that is the entire argument for self-funding early. The early money buys the milestones that make later capital cheaper, and from phase 3 onward the company is raising against proof rather than against a promise.

This is also the shape of what a company does to stay alive while it raises for something bigger. Peloton and Tonal both ran versions of this — build the thing, prove the demand, then raise against proof rather than against a promise.

Equity Is a Retention Tool, Not a Bonus

The reason to reserve an option pool on day zero isn't generosity, it's that equity is the only currency an early-stage company has enough of.

Two mechanics do the work:

Stock options give someone the right to buy a set number of shares at a fixed price later. They don't own anything until they exercise.

The strike price is what they pay to exercise. Incorporate early with a low par value and that price is close to nothing, so an early employee can buy their earned equity for pennies. Everything above it is upside.

Then vesting makes it a retention tool rather than a signing bonus. The standard is four years with a one-year cliff: leave before your first anniversary and you get nothing, hit the anniversary and 25% vests at once, and the rest drips quarterly over the following three years. It protects the company from a bad hire walking off with equity, and it gives a good hire a reason to still be there in year three.

Elon Musk is the clearest example of taking this seriously. Tesla and SpaceX have handed equity far deeper into the organization than most companies of their size, and his own compensation has famously been options tied to milestones rather than salary. Whatever you think of him, the structural point holds: when the people building the thing own a real piece of it, they behave like owners. Meaningful equity — even 0.2% to 2% — converts an employee into someone whose financial outcome is the company's outcome.

The Pitch Deck Is a Living Document

Line drawing of two figures either side of a large document, arrows circulating between them.
Every pitch is a data point. The deck should be different afterwards.

The deck is not an artifact you finish. It evolves with every round, every meeting, and every piece of feedback. It should be tailored to the audience — a sports league, a medtech fund, and an angel syndicate are three different conversations — and revised after every pitch to improve clarity, flow, and emotional connection.

If your deck is the same after twenty pitches as it was before them, you weren't listening. Rejection is data, and it's most of the data you're going to get.

What It Comes Down To

The odds are bad, the money is expensive, and most of the work happens before anyone sees a slide. What you actually control is how easy you make it to say yes: know which doors are open before you knock, raise in an order that makes each round cost less than the last, and give the people building it a real reason to stay.